HBsAg定量检测对恩替卡韦治疗HBeAg阴性慢性乙型肝炎患者停药后复发的预测效能

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract [Abstract]Objective To investigate the predictive efficiency of quantitative detection of Hepatitis B virus surface antigen（HBsAg）on the relapse of entecavir in patients with Hepatitis B virus antigen（HBeAg）negative chronic hepatitis B after discontinuation.Methods The clinical data of 83 outpatients with chronic hepatitis B treated with Entecavir from January 2016 to January 2017 were analyzed retrospectively，the patients were divided into relapse group（60 cases）and non relapse group（23 cases）according to the follow-up of 1 year，whether there was virological recurrence or not.The clinical data of relapse group and non relapse group were compared.The recurrence degree of HBsAg were compared in the relapse group at 6 and 12 months after drug withdrawal.Quantitative prediction of diagnostic efficacy of entecavir in relapsed group by HbsAg was analyzed.Results The baseline alanine aminotransferase（ALT），and HBsAg quantitative levels at the time of withdrawal were higher in the relapse group than those in the non-relapse group，the differences were statistically significant（P＜0.05）.There were no significant differences in gender，age，genotype，and incidence of cirrhosis and baseline Hepatitis B virus DNA（HBV DNA）between the two groups（P＞0.05）.The recurrence rate of different HBsAg quantitative levels in the relapse group at 12 months of discontinuation were higher than those at the 6 months of discontinuation，the difference was statistically significant（P＜0.05）.The area under the curve（AUC）for quantitative prediction of HBsAg discontinuation of entecavir withdrawal was 0.911（95%CI:0.828-0.962）.The optimal cutoff value for HBsAg quantification was 1.957 log10IU/ml，and the sensitivity and specificity were 85.00%and 98.00%，respectively.Conclusion Quantitative HBsAg level is more significant with the relapse time，and HBsAg quantitative detection has a higher diagnostic efficacy to predict relapse after entecavir discontinuation.

Key words： Chronic hepatitis B Entecavir Hepatitis B surface antigen quantitative Drug withdrawal and relapse Follow-up The recurrence rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I4/36

[1]	慢性乙型肝炎核苷（酸）类似物经治患者抗病毒治疗专家委员会.慢性乙型肝炎核苷（酸）类似物经治患者抗病毒治疗专家共识：2016年更新[J].中国肝脏病杂志（电子版），2016，8（3）：15-20.
[2]	European Association for the Study of the Liver.EASL 2017 clinical practice guidelines on the management of Hepatitis B virus infection[J].J Hepatol，2017，67（2）：370-398.
[3]	鲍腾，胡庆刚，叶珺，等.HBsAg 水平在慢性HBV 感染者疾病进展中的动态监测价值[J].临床肝胆病杂志，2017，33（8）：1475-1478.
[4]	齐健，陈新月.HBsAg在慢性HBV 感染中的研究进展[J].中国肝脏病杂志（电子版），2017，9（4）：22-26.
[5]	中华医学会肝病学分会，中华医学会感染病学分会.慢性乙型肝炎防治指南（2015年更新版）[J].临床肝胆病杂志，2015，31（12）：1641-1960.
[6]	邱源旺，黄利华，杨文龙，等.HBsAg 水平对HBeAg 阳性患者恩替卡韦停药后复发的预测价值[J].中华检验医学杂志，2015，38（11）：771-773.
[7]	Fung J，Wong T，Chok K，et al.Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation：results up to 8 years[J].Hepatology，2017，66（4）：1036-1044.
[8]	王昌生，岳晓荷，路淼.乙型肝炎病毒表面抗原定量检测对恩替卡韦停药后乙型肝炎复发的预测价值[J].中华实验和临床感染病杂志（电子版），2018，12（4）：386-391.
[9]	Chen CH，Hung CH，Wang JH，et al.The incidence of hepatitis B surface antigen loss between hepatitis B E antigennegative noncirrhotic patients who discontinued or continued entecavir therapy[J].J Infec Dis，2019，219（10）：1624-1633.
[10]	Wang CC，Tseng KC，Hsieh TY，et al.Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg[J].Am J Gastroenterol，2016，119（9）：1286-1294.
[11]	Lee HA，Seo YS，Park SW，et al.Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B[J].Clin Mol Hepatol，2016，22（3）：382-389.
[12]	周朝晖.恩替卡韦治疗e抗原阴性慢性乙型肝炎停药复发的分析[J].肝脏，2017，22（10）：882-884.
[13]	Hung CH，Wang JH，Lu SN，et al.Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analogue therapy[J].J Viral Hepat，2017，24（7）：599-607.
[14]	Ji M，Hu K.Recent advances in the study of Hepatitis B virus covalently closed circular DNA[J].Virol Sin，2017，32（6）：454-464.
[15]	Kim SH.ELISA for quantitative determination of Hepatitis B virus surface antigen[J].Immune Netw，2017，17（6）：451-459.